Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1354
- Registration Number
- NCT00281593
- Locations
- 🇺🇸
1236.1.573 Boehringer Ingelheim Investigational Site, Long Beach, California, United States
🇺🇸1236.1.560 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
🇺🇸1236.1.523 Boehringer Ingelheim Investigational Site, Buena Park, California, United States
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 812
- Registration Number
- NCT00274599
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Harold B. Betton, M.D., Little Rock, Arkansas, United States
🇺🇸GFI Pharmaceuticals, Evansville, Indiana, United States
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 801
- Registration Number
- NCT00274612
- Locations
- 🇦🇹
Rehabilitationszentrum für Herz- und Kreislauferkrankungen, Bad Tatzmannsdorf, Austria
🇦🇹Landeskrankenhaus Graz West, Graz, Austria
🇦🇹Univ.-Klinik für Innere Medizin III, Wien, Austria
DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT00274118
- Locations
- 🇳🇱
Bosch Medicentrum, Den Bosch, Netherlands
🇳🇴Hjertelaget Research Foundation, Stavanger, Norway
🇩🇰Medical Dept. B0642, Hillerød, Denmark
SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT00274105
- Locations
- 🇩🇪
Med. Hochschule Hannover, Hannover, Germany
🇩🇪Universitätsklinikum Charité, Berlin, Germany
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
- Conditions
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT00257491
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00240422
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Nürnberg, Germany
🇩🇪Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪Universität Erlangen-Nürnberg, Nürnberg, Germany
Treatment of Insulin Resistance in Hypertensive, Obese Adolescents
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT00185705
- Locations
- 🇺🇸
Stanford Medical Center, Stanford, California, United States
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 860
- Registration Number
- NCT00168857
- Locations
- 🇲🇽
Fracc. Magallanes, Acapulco Guerrero, Mexico
🇺🇸VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
🇹🇭Pramongkutklao Hospital, Bangkok, Thailand
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 885
- Registration Number
- NCT00153023
- Locations
- 🇨🇿
District Hospital Tabor, Tabor, Czech Republic
🇫🇷Hopital A.Mignot, Le Chesnay, France
🇨🇿University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.